marijuana stock news

CannaVEST Corp. (CANV)

 

Income Statement Get Income Statement for:
View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014
Total Revenue 2,714   2,693   1,860   3,006  
Cost of Revenue 1,083 1,418 738 1,210
Gross Profit 1,631   1,275   1,122   1,796  
Operating Expenses
Research Development 323 430 262 157
Selling General and Administrative 3,994 9,575 1,351 1,507
Non Recurring
Others
Total Operating Expenses
Operating Income or Loss (2,686) (8,730) (490) 132  
Income from Continuing Operations
Total Other Income/Expenses Net 37
Earnings Before Interest And Taxes (2,649) (8,136) (482) 7,425
Interest Expense 615 (615)
Income Before Tax (2,649) (8,752) (482) 8,040
Income Tax Expense
Minority Interest
Net Income From Continuing Ops (2,649) (8,752) (482) 15,940
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income (2,649) (8,752) (482) 8,040  
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares (2,649) (8,752) (482) 8,040  

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$MSRT Recruits Daniel Droller as Vice President of Business Development

MassRoots Recruits Daniel Droller as Vice President of Business Development MassRoots, Inc.…

Canopy Rivers Inc. (RIV.V) Announces Significant Increase in Health Canada Licensed Infrastructure

Canopy Rivers Announces Significant Increase in Health Canada Licensed Infrastructure at Vert…

TerrAscend Corp. (TRSSF) Welcomes Adult-Use Sales in New Jersey

TerrAscend Welcomes Adult-Use Sales in New Jersey TerrAscend Corp. (“TerrAscend” or the…

GW Pharmaceuticals (GWPH) and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

Meeting Highlights Include New Phase 3 Data for EPIDIOLEX in Tuberous Sclerosis…